These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 23249166

  • 21. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T, Kataoka Y, Ikegaki S, Saito E, Matsumoto H, Kaku S, Shimada M, Hirabayashi M.
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [Abstract] [Full Text] [Related]

  • 22. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.
    Clin Cancer Res; 2007 May 15; 13(10):2928-35. PubMed ID: 17504993
    [Abstract] [Full Text] [Related]

  • 23. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 24. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.
    Thorax; 2014 Oct 15; 69(10):895-902. PubMed ID: 25037982
    [Abstract] [Full Text] [Related]

  • 25. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
    Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF.
    Med Clin (Barc); 2009 Oct 03; 133(12):449-53. PubMed ID: 19783262
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.
    Lung; 2016 Jun 03; 194(3):409-17. PubMed ID: 27032653
    [Abstract] [Full Text] [Related]

  • 27. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
    Lung Cancer; 2008 Oct 03; 62(1):45-54. PubMed ID: 18394747
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Biomarkers for mesothelioma.
    Scherpereel A, Lee YC.
    Curr Opin Pulm Med; 2007 Jul 03; 13(4):339-443. PubMed ID: 17534183
    [Abstract] [Full Text] [Related]

  • 30. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.
    Arch Toxicol; 2011 Mar 03; 85(3):185-92. PubMed ID: 20737138
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR, Zhai J.
    Diagn Cytopathol; 2005 Mar 03; 32(3):137-44. PubMed ID: 15690333
    [Abstract] [Full Text] [Related]

  • 33. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
    Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW.
    Thorax; 2007 Jul 03; 62(7):569-76. PubMed ID: 17356060
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
    Zimling ZG, Jørgensen A, Santoni-Rugiu E.
    Histopathology; 2012 May 03; 60(6B):E96-105. PubMed ID: 22394205
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H, Meister M.
    Oncotarget; 2016 Nov 01; 7(44):71285-71297. PubMed ID: 27713145
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.